(a) Schematic of the sample preparation, (b) developed GFRPs samples modified, (c) samples for impact strength tests, (d) samples for compressive strength tests. by Shaban Gul (14309526)

Colistin-phage combinations decrease antibiotic resistance in <i>Acinetobacter baumannii</i> via changes in envelope architecture by Xiaoqing Wang (514179)

T and B cells are markedly decreased in the VAT of CD11c-MyD88 KO DIO mice. by Manikandan Subramanian (789856)

The increased apoptosis and the decreased cell proliferation during development of the cerebral cortex in <i>lag/lag</i> mice. by Kohei Fujikura (106428)

Sensitivity of N2A stable clones to GCV. by Elizabeth Wei-Chia Luo (11250668)

“…<p>(A–L) N2A, N2A-pGFAP-HSVtk, and N2A-pCMV-HSVtk cells were treated separately with 0, 1, 5, or 10 μg/ml of GCV for 5 days, and their live-cell phase images or fluorescent images were captured. …”

Sensitivity of U251 stable clones to GCV. by Elizabeth Wei-Chia Luo (11250668)

“…<p>U251, U251-pCMV-HSVtk, and U251-pGFAP-HSVtk cells were treated with 0, 1, 5, or10 μg/ml of GCV for 5 days. (A–D) Live-cell phase images of U251 parent cells displayed no cytotoxicity up to 10 μg/ml of GCV. …”

PD decreases miR-141 levels and the ERK/NF-κB (p65) signaling pathway. by Chuchu Qiao (8831285)

Patterns of nestin, GFAP, and βIII-tubulin expression in U251-pCMV-HSVtk cells. by Elizabeth Wei-Chia Luo (11250668)

“…(D–F) Filamentous expression of nestin was observed at day 5, day 7, and after recovery. U251-pCMV-HSVtk cells expressed GFAP strongly at day 0 (G), and then gradually decreased expression during 7 days of GCV treatment (H–K). …”

Serotype-specific penicillin non-susceptibility during different PCV periods in Iceland, Romania, Spain and Belgium [68, 69, 76, 78, 84, 85]. by Heloisa Ricci Conesa (18291210)

Agonist-induced currents in both TRPV1- and TRPM8-transfected neurons are decreased after prolonged exposure. by Devon C. Crawford (256278)

“…Similar to (A), menthol was added to the bath recording solution. …”

Introduction status of PCVs in European countries over time. by Heloisa Ricci Conesa (18291210)

Inhibition of Hsp90 abolished VEGF-mediated eNOS phosphorylation and decreased NO production and cell viability in BAECs. by Yuanzhuo Chen (802891)

Hypoxia increases the expressions of HIF-1α, decreased the activity of Akt and regulates the expressions of FoxOs in CMECs. by Shenwei Zhang (487865)

Additional file 10 of Single-cell profiling reveals a reduced epithelial defense system, decreased immune responses and the immune regulatory roles of different fibroblast subpopul... by Lin Lin (46073)

Impact of SARS‐CoV‐2 infection on T, B and NK cell numbers in severe and moderate patients (* P< 0.05, ** P< 0.01). by Sam Alahyari (12645313)

Data extraction grid. by Heloisa Ricci Conesa (18291210)

“…No homogenous trends were identified in incidence rates across countries, or in detection of S. pneumoniae as a cause of AOM over time. There were indications of a reduction in hospitalization rates (decreases between 24.5–38.8% points, depending on country, PCV type and time since PCV introduction) and antibiotic resistance (decreases between 14–24%, depending on country), following the widespread use of PCVs over time. …”

Incidence rates of AOM cases. by Heloisa Ricci Conesa (18291210)

“…No homogenous trends were identified in incidence rates across countries, or in detection of S. pneumoniae as a cause of AOM over time. There were indications of a reduction in hospitalization rates (decreases between 24.5–38.8% points, depending on country, PCV type and time since PCV introduction) and antibiotic resistance (decreases between 14–24%, depending on country), following the widespread use of PCVs over time. …”

Inclusion criteria. by Heloisa Ricci Conesa (18291210)

“…No homogenous trends were identified in incidence rates across countries, or in detection of S. pneumoniae as a cause of AOM over time. There were indications of a reduction in hospitalization rates (decreases between 24.5–38.8% points, depending on country, PCV type and time since PCV introduction) and antibiotic resistance (decreases between 14–24%, depending on country), following the widespread use of PCVs over time. …”

PRISMA flow diagram for the literature search. by Heloisa Ricci Conesa (18291210)

“…No homogenous trends were identified in incidence rates across countries, or in detection of S. pneumoniae as a cause of AOM over time. There were indications of a reduction in hospitalization rates (decreases between 24.5–38.8% points, depending on country, PCV type and time since PCV introduction) and antibiotic resistance (decreases between 14–24%, depending on country), following the widespread use of PCVs over time. …”

Estimates for direct medical and total costs per AOM episode (2020 EUR), by country [35, 96–100]. by Heloisa Ricci Conesa (18291210)